Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
Alpine Immune Sciences Announces $60 Million Private Placement
01:15pm, Friday, 24'th Jul 2020
Alpine Immune Sciences Announces $60 Million Private Placement
Did Business Growth Power Alpine Immune Sciences' (NASDAQ:ALPN) Share Price Gain of 126%?
10:45am, Wednesday, 22'nd Jul 2020
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shareholders have seen the share price descend 13% over the month. But that...
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
01:05pm, Wednesday, 08'th Jul 2020
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Alpine Immune Sciences, Inc. (ALPN) Shares March Higher, Can It Continue?
11:35am, Wednesday, 08'th Jul 2020
As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
04:09pm, Thursday, 25'th Jun 2020
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
12:00pm, Wednesday, 24'th Jun 2020
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
12:00am, Wednesday, 24'th Jun 2020
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
Alpine Immune Sciences, Inc. : The underlying trend is to the upside | MarketScreener
01:28pm, Tuesday, 23'rd Jun 2020Alpine Immune Sciences, Inc. : La tendance est haussière | Zone bourse
01:28pm, Tuesday, 23'rd Jun 2020Xconomy: Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better - Page 2 of 2
02:27am, Saturday, 20'th Jun 2020
Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy
Alpine Skyrockets on License Deal With AbbVie for ALPN-101
03:27pm, Friday, 19'th Jun 2020
Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.
Company News for Jun 19, 2020
01:32pm, Friday, 19'th Jun 2020
Companies in the news are: SPOT, ALPN, AESE, NEON
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
11:41am, Friday, 19'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) * ADC Therapeutics SA (NYSE: ADCT) * Adverum Biotech
Analyzing Alpine Immune Sciences (NASDAQ:ALPN) & Nabriva Therapeutics (NASDAQ:NBRV)
01:46am, Friday, 19'th Jun 2020
Alpine Immune Sciences (NASDAQ:ALPN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the stre
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
12:00am, Friday, 19'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 18)
ADC Therapeutics SA (NYSE:...
